http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Colorimetric Sensors for Toxic and Hazardous Gas Detection: A Review
Sung Hwan Cho,Jun Min Suh,Tae Hoon Eom,Taehoon Kim,Ho Won Jang 대한금속·재료학회 2021 ELECTRONIC MATERIALS LETTERS Vol.17 No.1
Since the industries are vastly rising, the threat of toxic and hazardous substance to human beings and demands of the accuratesensor is increasing. Colorimetric sensors that detect substances by measuring the absorbance or fluorescence spectra shiftare one of the most emerging strategies these days. However, conventional colorimetric gas sensors are limited to specificapplication due to the limitation of detecting only liquid phase substances. For practical applications of the colorimetric sensors,it is necessary to detect low concentrations of toxic and hazardous substances in gaseous media. Besides, operation withlow power consumption and excellent selectivity and sensitivity should be considered for Internet of Things (IoT) application. In this paper, various efforts on the investigation of several materials, including dyes, polymers, metal–organic complexes,and metal oxides as active sensor elements of the colorimetric gas sensors for IoT application are summarized. This paperalso reviews various kinds of colorimetric gas sensor that exhibit great sensing properties to toxic and hazardous gases andintroduce a brief overview of the challenges of colorimetric gas sensors as a candidate for future IoT gas sensor technology.
( Jang Wook Lee ),( Chang Hwan Choi ),( Ji Hoon Park ),( Jeong Wook Kim ),( Sang Bum Kang ),( Ja Seol Koo ),( Young Ho Kim ),( You Sun Kim ),( Young Eun Joo ),( Sae Kyung Chang ) 대한장연구학회 2016 Intestinal Research Vol.14 No.2
Background/Aims: Anti-tumor necrosis factor (TNF) therapy for active ulcerative colitis (UC) and Crohn`s disease (CD) is associated with increased risks of tuberculosis (TB) infection. We analyzed the incidence and clinical features of Korean patients with inflammatory bowel disease (IBD) who developed active TB during anti-TNF therapy. Methods: Ten cases of active TB developed in patients treated with infliximab (n=592) or adalimumab (n=229) for UC (n=160) or CD (n=661) were reviewed. We analyzed demographics, interval between start of anti-TNF therapy and active TB development, tests for latent TB infection (LTBI), concomitant medications, and the details of diagnosis and treatments for TB. Results: The incidence of active TB was 1.2% (10/821): 1.5% (9/592) and 0.4% (1/229) in patients receiving infliximab and adalimumab, respectively. The median time to the development of active TB after initiation of anti-TNF therapy was three months (range: 2-36). Three patients had past histories of treatment for TB. Positive findings in a TB skin test (TST) and/or interferon gamma releasing assay (IGRA) were observed in three patients, and two of them received anti-TB prophylaxis. Two patients were negative by both TST and IGRA. The most common site of active TB was the lungs, and the active TB was cured in all patients. Conclusions: Active TB can develop during anti-TNF therapy in IBD patients without LTBI, and even in those with histories of TB treatment or LTBI prophylaxis. Physicians should be aware of the potential for TB development during anti-TNF therapy, especially in countries with a high prevalence of TB. (Intest Res 2016;14:146-151)
Jang, Jiryeon,Rath, Oliver,Schueler, Julia,Sung, Hyun Hwan,Jeon, Hwang Gyun,Jeong, Byong Chang,Seo, Seong Il,Jeon, Seong Soo,Lee, Hyun Moo,Choi, Han-Yong,Kwon, Ghee-Young,Park, Woong Yang,Lee, Jeeyun Neoplasia Press 2017 Translational oncology Vol.10 No.3
<P><I>PURPOSE:</I> Although targeting angiogenesis with tyrosine kinase inhibitors (TKIs) has become standard of care in the treatment of clear cell renal cell carcinoma (RCC), resistance mechanism are not fully understood, and there is a need to develop new therapeutic options overcoming them. <I>METHODS AND MATERIALS:</I> To develop a preclinical model that predicts clinical activity of novel agents in 19 RCC patients, we established patient-derived cell (PDC) and xenograft (PDX) models derived from malignant effusions or surgical specimen. RESULTS: Successful PDCs, defined as cells that maintained growth following two passages, were established in 5 of 15 malignant effusions and 1 of 4 surgical specimens. One PDC, clinically refractory to TKIs, was implanted and engrafted in mice, resulting in a comparable histology to the primary tumor. The PDC-PDX model also showed similar genomic features when tested using targeted sequencing of cancer-related genes. When we examined the drug effects of the PDX model, the tumor cells showed resistance to TKIs and everolimus <I>in vitro</I>. <I>CONCLUSION:</I> The results suggest that the PDC-PDX preclinical model we developed using malignant effusions can be a useful preclinical model to interrogate sensitivity to targeted agents based on genomic alterations.</P>
Sung-Won Jang,Robert W Rho,Tae-Seok Kim,sung-hwan kim,woo-seung shin,Yong-Seog Oh,Man Young Lee,Eiwa Zen,Tai-Ho Rho,Ji-Hoon Kim 대한심장학회 2016 Korean Circulation Journal Vol.46 No.5
Background and Objectives: The number of permanent pacemakers (PPMs) implanted in patients in Japan and Korea differs significantly. We aimed to investigate the differences in decision making processes of implanting a PPM. Materials and Methods: Our survey included 15 clinical case scenarios based on the 2008 AHA/ACC/HRS guidelines for device-based therapy of cardiac rhythm abnormalities (class unspecified). Members of the Korean and Japanese Societies of Cardiology were asked to rate each scenario according to a 5-point scale and to indicate their decisions for or against implantation. Results: Eighty-nine Korean physicians and 192 Japanese physicians replied to the questionnaire. For the case scenarios in which there was a class I indication for PPM implantation, the decision to implant a PPM did not differ significantly between the two physician groups. However, the Japanese physicians were significantly more likely than the Korean physicians to choose implantation in class IIa scenarios (48% vs. 37%, p<0.001), class IIb scenarios (40% vs. 19%, p<0.001), and class III scenarios (36% vs. 18%, p<0.001). These results did not change when the cases were categorized based on disease entity, such as sinus node dysfunction and conduction abnormality. Conclusion: Korean physicians are less likely than Japanese physicians to favor a PPM implantation when considering a variety of clinical case scenarios, which probably contributes to the relatively small number of PPMs implanted in patients in Korea as compared with those in Japan.
Functional Connectivity Map of Retinal Ganglion Cells for Retinal Prosthesis
Jang Hee Ye,Sang Baek Ryu,Kyung Hwan Kim,Yong Sook Goo 대한생리학회-대한약리학회 2008 The Korean Journal of Physiology & Pharmacology Vol.12 No.6
Retinal prostheses are being developed to restore vision for the blind with retinal diseases such as retinitis pigmentosa (RP) or age-related macular degeneration (AMD). Among the many issues for prosthesis development, stimulation encoding strategy is one of the most essential electrophysiological issues. The more we understand the retinal circuitry how it encodes and processes visual information, the greater it could help decide stimulation encoding strategy for retinal prosthesis. Therefore, we examined how retinal ganglion cells (RGCs) in in-vitro retinal preparation act together to encode a visual scene with multielectrode array (MEA). Simultaneous recording of many RGCs with MEA showed that nearby neurons often fired synchronously, with spike delays mostly within 1 ms range. This synchronized firing - narrow correlation - was blocked by gap junction blocker, heptanol, but not by glutamatergic synapse blocker, kynurenic acid. By tracking down all the RGC pairs which showed narrow correlation, we could harvest 40 functional connectivity maps of RGCs which showed the cell cluster firing together. We suggest that finding functional connectivity map would be useful in stimulation encoding strategy for the retinal prosthesis since stimulating the cluster of RGCs would be more efficient than separately stimulating each individual RGC.
Jang, Hwan-Hee,Cho, Su-Yeon,Kim, Mi-Ju,Kim, Jung-Bong,Lee, Sung-Hyen,Lee, Mee-Young,Lee, Young-Min BioMed Central 2016 Biological research Vol.49 No.-
<P><B>Background</B></P><P>Asthma is an increasing global health problem, and novel strategies to prevent or ameliorate the condition are needed. Here, the effects of 80 % ethanol extracts of <I>Salvia plebeia</I> R. Br. (SE) on an induced inflammatory response were investigated.</P><P><B>Results</B></P><P><I>Salvia plebeia</I> R. Br. inhibited production of pro-inflammatory cytokines, such as TNF-α and IL-6, as well as nitric oxide (NO) in LPS-stimulated RAW 264.7 cells. NO and pro-inflammatory cytokine production was suppressed more effectively by SE of the aerial parts (SE-A) than of the roots (SE-R) of <I>S. plebeia</I>. In BEAS-2B cells, both SE-A and SE-R inhibited the increase in production of the inflammatory cytokines IL-6 and IL-8. We also investigated the anti-asthmatic effects of SE in an ovalbumin (OVA)-induced BALB/c mouse model. SE-A treatment significantly reduced the number of airway eosinophils, IL-4 and IL-13 levels, mucus production, and inflammatory infiltration, as compared with the corresponding levels in the untreated, OVA-induced mice, and had similar effects to dexamethasone.</P><P><B>Conclusions</B></P><P><I>Salvia plebeia</I> ethanol extract ameliorated the induced inflammatory response in RAW 264.7 and BEAS-2B cells, with more effective inhibition noted for SE-A than for SE-R. SE-A treatment was effective in improving the histopathological changes in the lungs of asthma model mice via modulation of eosinophils and Th2 cytokines. These results suggest that SE-A can be considered as a therapeutic agent that can potentially relieve asthma.</P>